D-Glutamate

D-Glutamate

SCHEMBL718336

N[C@@H](CCC(=O)O)C(=O)[O-].N[C@@H](CCC(=O)O)C(=O)[O-].[Fe+2]

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.62
GRM8 O00222 1/20 0.62
GRM6 O15303 1/20 0.62
GRIN2D O15399 1/20 0.62
GRIN3B O60391 1/20 0.62
GSR P00390 1/20 0.62
GRIK1 P39086 1/20 0.62
GRM5 P41594 1/20 0.62
GRIA1 P42261 1/20 0.62
GRIA2 P42262 1/20 0.62
GRIA3 P42263 1/20 0.62
SLC1A3 P43003 1/20 0.62
SLC1A2 P43004 1/20 0.62
SLC1A1 P43005 1/20 0.62
GRIA4 P48058 1/20 0.62
GRIN1 Q05586 1/20 0.62
GRIN2A Q12879 1/20 0.62
GRIK2 Q13002 1/20 0.62
GRIK3 Q13003 1/20 0.62
GRIN2B Q13224 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
D-Glutamate SCHEMBL6738798 0.95 CYP1A2 (0.62) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL16336 0.95 CYP1A2 (0.62) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL218574 0.95 CYP1A2 (0.62) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL11884703 0.95 CYP1A2 (0.62) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL1782280 0.95 CYP1A2 (0.62) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL8746869 0.95 CYP1A2 (0.62) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL1899059 0.95 CYP1A2 (0.62) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL1532402 0.95 CYP1A2 (0.62) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL5184074 0.95 GRM8 (0.62) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL5207959 0.95 CYP1A2 (0.62) CYP1A2GRM8GRM6GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024253189-A1 PROPHYLACTIC AND/OR AMELIORATING AGENT FOR PERIPHERAL NEUROPATHY CAUSED BY CANCER CHEMOTHERAPEUTIC AGENT 国立大学法人 富山大学 2024-12-12 WO claimed
US-11224222-B2 Synergistic compositions of dehydroacetic acid and methods for reducing yellowing in various end-user compositions ISP INVESTMENTS LLC (US) 2022-01-18 US claimed
CN-113735729-A Production process of feed-grade ferrous glutamate 四川吉隆达生物科技集团有限公司 2021-12-03 CN claimed
CN-107613954-B Synergistic compositions of dehydroacetic acid and methods of reducing yellowing in various end-use compositions ISP投资有限公司 2021-10-19 CN claimed
CN-109180510-B Preparation method of high-purity ferrous glutamate 长沙兴嘉生物工程股份有限公司 2021-08-24 CN claimed
WO-2021137780-A1 PREPARATION OF FILM TABLET COMPOSITION COMPRISING HEME IRON FOR IRON DEFICIENCY İLKO İLAÇ SANAYİ VE TİCARET A.Ş. (TR) 2021-07-08 WO claimed
EP-3216782-B1 IRON AMINO ACID COMPOUNDS, METHOD FOR PREPARING IRON AMINO ACID COMPOUNDS, COMPOSITIONS CONTAINING IRON AMINO ACID COMPOUNDS, AND USES THEREOF NPA NUCLEO DE PESQUISAS APLICADAS LTDA (BR) 2021-06-02 EP claimed
US-20210122705-A1 IRON AMINO ACID COMPOUNDS, METHOD FOR PREPARING IRON AMINO ACID COMPOUNDS, COMPOSITIONS CONTAINING IRON AMINO ACID COMPOUNDS, AND USES THEREOF NPA NUCLEO DE PESQUISAS APLICADAS LTDA (BR) 2021-04-29 US claimed
CN-112675160-A Amino acid mineral salt trace element composition and preparation method thereof 河北力维素科技有限公司 2021-04-20 CN claimed
CN-110791277-A Fracturing fluid capable of being converted into oil displacement agent without flowback for oil field and preparation method thereof 西安石油大学 2020-02-14 CN claimed
EP-0966209-A1 COOKED CEREAL INGREDIENT-CONTAINING PRODUCTS FORTIFIED WITH EDTA/IRON COMPOSITIONS AND METHODS FOR USE KELLOGG COMPANY (US) 1999-12-29 EP claimed
WO-1999005920-A1 COOKED CEREAL INGREDIENT-CONTAINING PRODUCTS FORTIFIED WITH EDTA/IRON COMPOSITIONS AND METHODS FOR USE KELLOGG COMPANY (US) 1999-02-11 WO claimed
US-5869084-A SPECIFIC REGIMENS FOR LACTATING, NON-LACTATING AND MENOPAUSAL WOMEN K-V PHARMACEUTICALS CO. (US) 1999-02-09 US claimed
EP-0748166-A4 READY-TO-EAT CEREAL PRODUCT FORTIFIED WITH FERRIC EDTA KELLOG CO (US) 1997-07-16 EP claimed
EP-0748166-A1 READY-TO-EAT CEREAL PRODUCT FORTIFIED WITH FERRIC EDTA KELLOGG COMPANY (US) 1996-12-18 EP claimed
US-5534275-A Foodstuffs containing a cereal ingredient and ferric EDTA KELLOGG COMPANY (US) 1996-07-09 US claimed
WO-1995035098-A1 MULTI-VITAMIN AND MINERAL SUPPLEMENTS FOR WOMEN KV PHARMACEUTICAL COMPANY (US) 1995-12-28 WO claimed
WO-1995022908-A1 READY-TO-EAT CEREAL PRODUCT FORTIFIED WITH FERRIC EDTA KELLOGG COMPANY (US) 1995-08-31 WO claimed
US-5045337-A Mixture of lipid, polar solvent, and polyglycerol THE PROCTER & GAMBLE COMPANY (US) 1991-09-03 US claimed
EP-0366058-A2 Controlled-release delivery device, method for producing device, and method of using device ABBOTT LABORATORIES (US) 1990-05-02 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210122705-A1 IRON AMINO ACID COMPOUNDS, METHOD FOR PREPARING IRON AMINO ACID COMPOUNDS, COMPOSITIONS CONTAINING IRON AMINO ACID COMPOUNDS, AND USES THEREOF HAMP, FECH, TFRC CYP1A2 2124/4885GRM8 1646/4885GRM6 712/4885
US-11224222-B2 Synergistic compositions of dehydroacetic acid and methods for reducing yellowing in various end-user compositions ALAD, SCD, DHCR7 CYP1A2 264/4885GRM8 3496/4885GRM6 1472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.